Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions January 14, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules January 13, 2021 • 4:05 PM EST
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules January 11, 2021 • 12:59 PM EST
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection January 5, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility December 23, 2020 • 9:00 AM EST
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin) December 22, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans December 21, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia December 7, 2020 • 7:00 AM EST
Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus December 4, 2020 • 8:00 AM EST
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates November 16, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit November 12, 2020 • 4:31 PM EST
Tonix Pharmaceuticals to Participate in Upcoming November Conferences November 11, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit November 9, 2020 • 4:15 PM EST
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights November 9, 2020 • 8:30 AM EST
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics October 15, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis September 29, 2020 • 4:05 PM EDT
Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs September 28, 2020 • 4:15 PM EDT
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19? September 17, 2020 • 9:17 AM EDT
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19 September 15, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia September 3, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences August 27, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights August 10, 2020 • 8:45 AM EDT
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder August 6, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement August 4, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference August 4, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference July 30, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference July 27, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders July 21, 2020 • 4:45 PM EDT
Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics July 16, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering July 15, 2020 • 5:00 PM EDT
Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering July 13, 2020 • 1:11 PM EDT
Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19 July 13, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia July 10, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics July 7, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule June 29, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020 June 22, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration June 18, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020 June 17, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License June 11, 2020 • 2:43 PM EDT
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors June 10, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences June 3, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800 June 1, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology May 21, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine May 19, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights May 12, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19 May 7, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia April 24, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020 April 20, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights March 24, 2020 • 5:15 PM EDT
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit March 23, 2020 • 4:30 PM EDT
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering March 3, 2020 • 5:00 PM EST
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market February 28, 2020 • 8:45 AM EST
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) February 26, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering February 11, 2020 • 4:01 PM EST
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD February 5, 2020 • 5:15 PM EST
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences February 4, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 29, 2020 • 4:15 PM EST
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL January 24, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 23, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study December 16, 2019 • 3:15 PM EST
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL December 11, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia December 10, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 3, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD November 26, 2019 • 4:05 PM EST
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference November 25, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia November 21, 2019 • 8:00 AM EST
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder November 20, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering November 20, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights November 8, 2019 • 4:45 PM EST
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting November 4, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 October 23, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD October 7, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg October 3, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers September 16, 2019 • 4:15 PM EDT
Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology September 16, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference September 12, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences September 10, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder September 4, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection August 21, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD August 20, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights August 12, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL July 25, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock July 18, 2019 • 4:05 PM EDT
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock July 16, 2019 • 8:30 AM EDT
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL June 13, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 30, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication May 23, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala May 22, 2019 • 4:19 PM EDT
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 21, 2019 • 4:15 PM EDT
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights May 13, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA May 8, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) April 23, 2019 • 1:51 PM EDT
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder April 22, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia April 4, 2019 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights March 18, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder March 11, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder March 1, 2019 • 5:41 PM EST
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion January 2, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 18, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering December 11, 2018 • 4:00 PM EST
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes November 29, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights November 9, 2018 • 7:30 AM EST
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya® November 7, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018 November 6, 2018 • 7:00 AM EST
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference November 1, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting October 31, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018 October 29, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference October 23, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference September 20, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences August 30, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium August 21, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium August 15, 2018 • 11:46 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights August 13, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD July 27, 2018 • 8:00 AM EDT
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease July 16, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology May 31, 2018 • 4:30 PM EDT
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL May 24, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology May 23, 2018 • 4:05 PM EDT
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update May 14, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention May 7, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease May 1, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York April 4, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD April 3, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL March 21, 2018 • 4:05 PM EDT
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium March 13, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update March 12, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors February 15, 2018 • 7:00 AM EST
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City February 7, 2018 • 4:30 PM EST
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale January 24, 2018 • 4:30 PM EST
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) January 23, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture) January 19, 2018 • 2:00 PM EST
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer January 9, 2018 • 7:00 AM EST
Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco January 3, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease December 12, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference November 30, 2017 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update November 7, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference November 1, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD October 17, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference October 12, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C. September 29, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) September 14, 2017 • 4:05 PM EDT
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors September 14, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference September 6, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium August 29, 2017 • 4:30 PM EDT
Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium August 21, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update August 14, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD July 6, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the 2017 BIO International Convention June 16, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense June 15, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference June 12, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study May 30, 2017 • 4:30 PM EDT
Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting May 24, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD May 22, 2017 • 4:05 PM EDT
Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update May 15, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention May 11, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use May 2, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update April 17, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option April 13, 2017 • 11:30 AM EDT
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder April 11, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock April 4, 2017 • 11:30 AM EDT
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement April 3, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock March 30, 2017 • 8:01 AM EDT
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock March 29, 2017 • 4:07 PM EDT
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference March 29, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL March 28, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference March 15, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL March 14, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference March 7, 2017 • 7:00 AM EST
Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus March 2, 2017 • 7:24 AM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference February 28, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference February 9, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13 January 24, 2017 • 7:00 AM EST
Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference January 10, 2017 • 1:00 PM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference January 3, 2017 • 7:00 AM EST
Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA December 19, 2016 • 7:00 AM EST
Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD) December 8, 2016 • 7:00 AM EST
Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) December 2, 2016 • 7:21 AM EST
Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference November 30, 2016 • 7:00 AM EST
Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD November 10, 2016 • 7:00 AM EST
Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting November 7, 2016 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference November 2, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress November 1, 2016 • 4:30 PM EDT
Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering October 31, 2016 • 4:30 PM EDT
Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering October 26, 2016 • 8:46 AM EDT
Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants October 25, 2016 • 5:15 PM EDT
Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day October 19, 2016 • 7:00 AM EDT
UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference October 18, 2016 • 5:48 PM EDT
Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference October 13, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum September 26, 2016 • 9:00 AM EDT
Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference September 7, 2016 • 7:39 AM EDT
Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update September 6, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder August 29, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium August 15, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update August 8, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia July 26, 2016 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option July 12, 2016 • 4:30 PM EDT
Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference July 7, 2016 • 4:05 PM EDT
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock June 21, 2016 • 12:00 PM EDT
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference June 17, 2016 • 8:00 AM EDT
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock June 16, 2016 • 8:00 AM EDT
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia June 9, 2016 • 10:30 AM EDT
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting May 31, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting May 26, 2016 • 8:30 AM EDT
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) May 19, 2016 • 6:00 AM EDT
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update May 9, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia May 2, 2016 • 7:05 AM EDT
Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference March 29, 2016 • 7:00 AM EDT
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting March 9, 2016 • 7:00 AM EST
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update March 4, 2016 • 7:00 AM EST
Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016 March 3, 2016 • 7:00 AM EST
Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache February 16, 2016 • 8:00 AM EST
Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference February 2, 2016 • 7:05 AM EST
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) December 23, 2015 • 7:00 AM EST
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache December 8, 2015 • 7:00 AM EST
Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder December 7, 2015 • 7:00 AM EST
Tonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference December 1, 2015 • 7:00 AM EST
Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting November 10, 2015 • 8:30 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update November 9, 2015 • 7:00 AM EST
Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting October 1, 2015 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment September 24, 2015 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference September 8, 2015 • 7:05 AM EDT
Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium August 18, 2015 • 1:00 PM EDT
Tonix Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Program Update August 10, 2015 • 7:00 AM EDT
Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development July 21, 2015 • 7:05 AM EDT
Tonix Pharmaceuticals Closes $20.1 Million Public Offering of Common Stock July 17, 2015 • 12:00 PM EDT
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock July 14, 2015 • 8:30 AM EDT
Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society June 22, 2015 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg June 17, 2015 • 7:15 AM EDT
Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache June 16, 2015 • 7:15 AM EDT
Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR June 11, 2015 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference May 28, 2015 • 8:40 AM EDT
Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR May 26, 2015 • 3:45 PM EDT
Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry May 15, 2015 • 9:00 AM EDT
Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia May 13, 2015 • 6:00 AM EDT
Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update May 11, 2015 • 6:00 AM EDT
Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference March 20, 2015 • 11:30 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results March 3, 2015 • 8:00 AM EST
Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum March 2, 2015 • 8:40 AM EST
Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock February 9, 2015 • 1:45 PM EST
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock February 4, 2015 • 1:15 PM EST
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock February 3, 2015 • 9:02 PM EST
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder January 15, 2015 • 7:00 AM EST
Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference January 14, 2015 • 8:40 AM EST
Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache January 9, 2015 • 7:00 AM EST
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia January 6, 2015 • 7:00 AM EST
Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache October 21, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia September 29, 2014 • 6:00 AM EDT
Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference September 19, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference September 3, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million July 11, 2014 • 8:20 AM EDT
Tonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. as Senior Vice President of Commercial Planning and Development June 26, 2014 • 8:30 AM EDT
Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder June 10, 2014 • 8:30 AM EDT
Tonix Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference May 29, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel May 20, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia May 12, 2014 • 8:40 AM EDT
Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Regulatory Affairs April 1, 2014 • 8:45 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results March 31, 2014 • 9:15 AM EDT
Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014 March 3, 2014 • 9:35 AM EST
Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock January 29, 2014 • 11:15 AM EST
Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million January 24, 2014 • 8:20 AM EST
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock January 23, 2014 • 4:02 PM EST
Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study December 10, 2013 • 8:40 AM EST
Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference November 26, 2013 • 8:40 AM EST
Tonix Pharmaceuticals Partners With the American Chronic Pain Association to Help Raise Awareness About Fibromyalgia October 24, 2013 • 8:45 AM EDT
Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 October 11, 2013 • 9:27 AM EDT
Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients September 16, 2013 • 8:01 AM EDT
Tonix Pharmaceuticals to Present at the First Global Life Sciences Conference in Warsaw, Poland on September 17, 2013 September 12, 2013 • 8:00 AM EDT
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013 September 4, 2013 • 8:00 AM EDT
Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome August 19, 2013 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Pricing of Public Offering of Units and NASDAQ Listing August 9, 2013 • 8:35 AM EDT
Tonix Pharmaceuticals to Hold Annual Shareholders' Meeting on April 19, 2013 April 11, 2013 • 8:05 AM EDT
TONIX Completes Pre-Phase 3 Meeting With U.S. Food and Drug Administration for TNX-102 SL in Fibromyalgia March 11, 2013 • 7:56 AM EDT
Tonix Pharmaceuticals to Present at the SeeThruEquity MicroCap Investor Forum on March 12 March 8, 2013 • 7:55 AM EST
Tonix Pharmaceuticals Completes $1 Million Financing With Technology Partners December 27, 2012 • 8:00 AM EST
Tonix Pharmaceuticals Presents Research Findings at the 2012 American College of Rheumatology Annual Scientific Meeting November 13, 2012 • 8:00 AM EST
TONIX Pharmaceuticals Completes Pre-IND Meeting With FDA for Potential New Treatment for Post-Traumatic Stress Disorder October 24, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet October 23, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals to Present at 2012 AEGIS Healthcare Conference September 24, 2012 • 8:00 AM EDT
TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting September 19, 2012 • 8:38 AM EDT
TONIX Pharmaceuticals' CEO Discusses the Company's New Treatment for Fibromyalgia on News-Medical.net September 6, 2012 • 8:00 AM EDT
TONIX Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Global Investment Conference on September 11 September 5, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals' CEO Highlights Connection Between Disturbed Sleep and New Treatment for Fibromyalgia and Post-Traumatic Stress Disorder on KIDELA TV August 27, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury August 16, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment August 14, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Completion of Clinical Trial of Sublingual TNX-102 July 30, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals Reports Positive Preclinical Data on Sublingual TNX-102 July 9, 2012 • 8:00 AM EDT
Tonix Pharmaceuticals to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28 June 27, 2012 • 11:00 AM EDT
Tonix Pharmaceuticals Receives Health Canada Clearance to Study a Novel Treatment for Fibromyalgia June 27, 2012 • 8:00 AM EDT
CORRECTING and REPLACING Tonix Pharmaceuticals Appoints Dr. Samuel Saks to Its Board of Directors May 10, 2012 • 9:32 PM EDT
TONIX Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia April 5, 2012 • 5:40 PM EDT
TONIX Pharmaceuticals Strengthens Management Team with the Appointments of Its New Chief Financial Officer and Senior Director of Drug Development April 4, 2012 • 6:04 AM EDT
TONIX Pharmaceuticals Holding Corp. Closes on Net Proceeds of $2.0 Million in Second Tranche of a $6.6 Million Private Placement March 6, 2012 • 6:04 AM EST
TONIX Pharmaceuticals to Present at the 14th Annual Bio CEO & Investor Conference on February 14, 2012 February 7, 2012 • 6:01 AM EST
Tonix Pharmaceuticals to Present at Biotech Showcase and OneMedForum Conferences in San Francisco on January 9 and 10, 2012 January 4, 2012 • 6:05 AM EST
TONIX Pharmaceuticals to Present at the New York Society of Security Analysts’ 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011 November 21, 2011 • 6:05 AM EST
Tonix Pharmaceuticals Receives FDA Clearance to Initiate a Pharmacokinetic Study of TNX-102 For Fibromyalgia November 18, 2011 • 7:30 AM EST
Tamandare Explorations Inc. Announces Name Change to Tonix Pharmaceuticals Holding Corp. October 20, 2011 • 9:00 AM EDT
TONIX Pharmaceuticals and Tamandare Explorations Announce Completion of Share Exchange Transaction and Private Placement October 14, 2011 • 9:00 AM EDT
Tonix Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology September 7, 2011 • 9:00 AM EDT
Tonix Pharmaceuticals Elects Harvey Moldofsky, M.D., to its Scientific Advisory Board June 20, 2011 • 9:00 AM EDT
TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome June 16, 2011 • 9:00 AM EDT
TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS) November 9, 2010 • 9:00 AM EST
TONIX Pharmaceuticals Elects Ernest Mario, PhD, to its Board of Directors November 8, 2010 • 9:00 AM EST